Novartis Ag (NVS) Shares Outstanding (2018 - 2025)
Novartis Ag recorded quarterly Shares Outstanding of $1.9 billion in Q4 2025, down 3.39% quarter-over-quarter from $2.0 billion in Q4 2024, and down 3.39% year-over-year from $2.0 billion in Q4 2024.
Novartis Ag's Shares Outstanding history runs 8 years deep, the most recent figure standing at $1.9 billion for Q4 2025.
- In Q4 2025, Shares Outstanding fell 3.39% year-over-year to $1.9 billion; the TTM figure through Dec 2025 stood at $1.9 billion (down 3.39% YoY), while the FY2025 annual figure was $1.9 billion, down 3.39% from the prior year.
- Shares Outstanding came in at $1.9 billion for Q4 2025 at Novartis Ag, down from $2.0 billion in the prior quarter.
- In the past five years, Shares Outstanding ranged from a high of $2.2 billion in Q4 2021 to a low of $1.9 billion in Q4 2025.
- A 5-year average of $2.1 billion and a median of $2.0 billion in 2023 frame the typical range for Shares Outstanding.
- Across the five-year window, Shares Outstanding retreated 0.97% in 2021 and declined 5.16% in 2022, its largest moves.
- Novartis Ag's Shares Outstanding stood at $2.2 billion in 2021, then fell by 5.16% to $2.1 billion in 2022, then slipped by 3.57% to $2.0 billion in 2023, then declined by 3.37% to $2.0 billion in 2024, then fell by 3.39% to $1.9 billion in 2025.
- According to Business Quant data, Shares Outstanding over the past three periods registered $1.9 billion, $2.0 billion, and $2.0 billion for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 943.50 Mn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 3.12 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 1.84 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 3.58 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 539.70 Mn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 1.24 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 9.64 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 2.92 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 5.74 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.91 Bn |
| Dec 31, 2025 | 1.91 Bn |
| Dec 31, 2025 | 1.91 Bn |
| Dec 31, 2025 | 1.91 Bn |
| Dec 31, 2025 | 1.91 Bn |
| Dec 31, 2025 | 1.91 Bn |
| Dec 31, 2025 | 1.91 Bn |
| Dec 31, 2025 | 1.91 Bn |
| Dec 31, 2024 | 1.98 Bn |
| Dec 31, 2024 | 1.98 Bn |
| Dec 31, 2024 | 1.98 Bn |
| Dec 31, 2024 | 1.98 Bn |
| Dec 31, 2024 | 1.98 Bn |
| Dec 31, 2024 | 1.98 Bn |
| Dec 31, 2024 | 1.98 Bn |
| Dec 31, 2024 | 1.98 Bn |
| Dec 31, 2023 | 2.04 Bn |
| Dec 31, 2023 | 2.04 Bn |
| Dec 31, 2023 | 2.04 Bn |
| Dec 31, 2023 | 2.04 Bn |
| Dec 31, 2023 | 2.04 Bn |
| Dec 31, 2023 | 2.04 Bn |
| Dec 31, 2023 | 2.04 Bn |
| Dec 31, 2023 | 2.04 Bn |
| Dec 31, 2022 | 2.12 Bn |
| Dec 31, 2022 | 2.12 Bn |
| Dec 31, 2022 | 2.12 Bn |
| Dec 31, 2022 | 2.12 Bn |
| Dec 31, 2022 | 2.12 Bn |
| Dec 31, 2022 | 2.12 Bn |
| Dec 31, 2022 | 2.12 Bn |
| Dec 31, 2022 | 2.12 Bn |
| Dec 31, 2021 | 2.23 Bn |
| Dec 31, 2021 | 2.23 Bn |
| Dec 31, 2021 | 2.23 Bn |
| Dec 31, 2021 | 2.23 Bn |
| Dec 31, 2021 | 2.23 Bn |
| Dec 31, 2021 | 2.23 Bn |
| Dec 31, 2021 | 2.23 Bn |
| Dec 31, 2021 | 2.23 Bn |
| Dec 31, 2020 | 2.26 Bn |
| Dec 31, 2020 | 2.26 Bn |
| Dec 31, 2020 | 2.26 Bn |
| Dec 31, 2020 | 2.26 Bn |
| Dec 31, 2020 | 2.26 Bn |
| Dec 31, 2020 | 2.26 Bn |
| Dec 31, 2020 | 2.26 Bn |
| Dec 31, 2020 | 2.26 Bn |
| Dec 31, 2019 | 2.27 Bn |
| Dec 31, 2019 | 2.27 Bn |
| Dec 31, 2019 | 2.27 Bn |
| Dec 31, 2019 | 2.27 Bn |
| Dec 31, 2019 | 2.27 Bn |
| Dec 31, 2019 | 2.27 Bn |
| Dec 31, 2019 | 2.27 Bn |
| Dec 31, 2019 | 2.27 Bn |
| Dec 31, 2018 | 2.31 Bn |
| Dec 31, 2018 | 2.31 Bn |
| Dec 31, 2018 | 2.31 Bn |
| Dec 31, 2018 | 2.31 Bn |
| Dec 31, 2018 | 2.31 Bn |
| Dec 31, 2018 | 2.31 Bn |
| Dec 31, 2018 | 2.31 Bn |
| Dec 31, 2018 | 2.31 Bn |